FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313248601> ?p ?o ?g. }

• W4313248601 endingPage "1923" @default.
• W4313248601 startingPage "1908" @default.
• W4313248601 abstract "Identifying the high recurrence group of patients with early-stage papillary thyroid cancer (PTC) is the greatest challenge in the management of this disease. It has been noted that B-type Rafkinase (BRAF) V600E mutation and programmed death ligand 1 (PD-L1) are associated in PTC and highly expressed in PTC, correlating in PTC as potential prognostic biomarkers. However, whether they can be used to predict the aggressiveness and recurrence of early PTC remains unclear.Clinicopathological data of 137 patients with early PTC [tumor-node-metastasis (TNM) stage I-II] who underwent surgery in Zhejiang Cancer Hospital between 2008 and 2010 were retrospectively analyzed. BRAFV600E mutation and PD-L1 was detected by immunohistochemistry. The median follow-up time was 136 months (interquartile range 5.8). The presence of tumor confirmed by imaging or pathology or lymph node metastasis was considered as tumor recurrence. The association of both alone and in combination with clinicopathological features and recurrence was statistically analyzed respectively. The risk of recurrence was assessed using Cox regression models.Most of the 137 early PTC were female (78.1%). The mean age was 43.2±12.1 years. The median tumor size was 1.4 cm; 14 patients developed recurrence during follow-up period; 56 patients (40.9%) were detected positive for BRAFV600E mutation; 76 patients (55.5%) were detected positive for PD-L1. Patients with both BRAFV600E mutation and PD-L1 expression had larger tumors (P=0.038), were more likely to have extrathyroidal invasion (P=0.045), and had a lower rate of cervical lymph node metastasis (P=0.046). The recurrence rate was 17.5% (7/40) in patients with BRAFV600E mutation and PD-L1 double expression compared to 8.9% (4/45) in patients with BRAFV600E mutation and PD-L1 double negative [hazard ratio (HR) =1.267; 95% CI: 0.841-1.909; P=0.257]. Survival curves showed flatter recurrence-free survival (RFS) curves in positive BRAFV600E mutation only and PD-L1 expression only, whereas decreased sharply in positive expression of both BRAFV600E mutation and PD-L1; however, the differences were not significant (P>0.05).The combination of BRAFV600E mutation and PD-L1 to identify group at higher risk of recurrence in early PTC has insufficient clinical evidence and should be used with caution in the clinical management of PTC." @default.
• W4313248601 created "2023-01-06" @default.
• W4313248601 creator A5005198186 @default.
• W4313248601 creator A5007384450 @default.
• W4313248601 creator A5023862346 @default.
• W4313248601 creator A5047406489 @default.
• W4313248601 creator A5051123701 @default.
• W4313248601 creator A5061976160 @default.
• W4313248601 creator A5071432504 @default.
• W4313248601 date "2022-12-01" @default.
• W4313248601 modified "2023-09-30" @default.
• W4313248601 title "Combined expression of the BRAFV600E mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence—a retrospective cohort study" @default.
• W4313248601 cites W1538981488 @default.
• W4313248601 cites W1561283197 @default.
• W4313248601 cites W1869029218 @default.
• W4313248601 cites W1952061311 @default.
• W4313248601 cites W2012288557 @default.
• W4313248601 cites W2016983859 @default.
• W4313248601 cites W2047604097 @default.
• W4313248601 cites W2049171090 @default.
• W4313248601 cites W2056671717 @default.
• W4313248601 cites W2059729332 @default.
• W4313248601 cites W2062493935 @default.
• W4313248601 cites W2095180807 @default.
• W4313248601 cites W2101888941 @default.
• W4313248601 cites W2116542352 @default.
• W4313248601 cites W2118986295 @default.
• W4313248601 cites W2130662884 @default.
• W4313248601 cites W2171379946 @default.
• W4313248601 cites W2332521027 @default.
• W4313248601 cites W2341622444 @default.
• W4313248601 cites W2556903147 @default.
• W4313248601 cites W2573152477 @default.
• W4313248601 cites W2797208234 @default.
• W4313248601 cites W2906522068 @default.
• W4313248601 cites W2922772115 @default.
• W4313248601 cites W2968456699 @default.
• W4313248601 cites W2972775239 @default.
• W4313248601 cites W3006516488 @default.
• W4313248601 cites W3009094826 @default.
• W4313248601 cites W3017682331 @default.
• W4313248601 cites W3032358754 @default.
• W4313248601 cites W3038464126 @default.
• W4313248601 cites W3044004652 @default.
• W4313248601 cites W3047147978 @default.
• W4313248601 cites W3047226952 @default.
• W4313248601 cites W3049484108 @default.
• W4313248601 cites W3092081304 @default.
• W4313248601 cites W3119005666 @default.
• W4313248601 cites W3128931577 @default.
• W4313248601 cites W3177182225 @default.
• W4313248601 cites W3203040890 @default.
• W4313248601 cites W4280498200 @default.
• W4313248601 doi "https://doi.org/10.21037/gs-22-701" @default.
• W4313248601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36654945" @default.
• W4313248601 hasPublicationYear "2022" @default.
• W4313248601 type Work @default.
• W4313248601 citedByCount "3" @default.
• W4313248601 countsByYear W43132486012023 @default.
• W4313248601 crossrefType "journal-article" @default.
• W4313248601 hasAuthorship W4313248601A5005198186 @default.
• W4313248601 hasAuthorship W4313248601A5007384450 @default.
• W4313248601 hasAuthorship W4313248601A5023862346 @default.
• W4313248601 hasAuthorship W4313248601A5047406489 @default.
• W4313248601 hasAuthorship W4313248601A5051123701 @default.
• W4313248601 hasAuthorship W4313248601A5061976160 @default.
• W4313248601 hasAuthorship W4313248601A5071432504 @default.
• W4313248601 hasBestOaLocation W43132486011 @default.
• W4313248601 hasConcept C119060515 @default.
• W4313248601 hasConcept C121608353 @default.
• W4313248601 hasConcept C126322002 @default.
• W4313248601 hasConcept C142724271 @default.
• W4313248601 hasConcept C143998085 @default.
• W4313248601 hasConcept C146357865 @default.
• W4313248601 hasConcept C151730666 @default.
• W4313248601 hasConcept C167135981 @default.
• W4313248601 hasConcept C204232928 @default.
• W4313248601 hasConcept C2779761222 @default.
• W4313248601 hasConcept C2780849966 @default.
• W4313248601 hasConcept C2781461381 @default.
• W4313248601 hasConcept C2993294228 @default.
• W4313248601 hasConcept C50382708 @default.
• W4313248601 hasConcept C526584372 @default.
• W4313248601 hasConcept C71924100 @default.
• W4313248601 hasConcept C86803240 @default.
• W4313248601 hasConcept C90924648 @default.
• W4313248601 hasConceptScore W4313248601C119060515 @default.
• W4313248601 hasConceptScore W4313248601C121608353 @default.
• W4313248601 hasConceptScore W4313248601C126322002 @default.
• W4313248601 hasConceptScore W4313248601C142724271 @default.
• W4313248601 hasConceptScore W4313248601C143998085 @default.
• W4313248601 hasConceptScore W4313248601C146357865 @default.
• W4313248601 hasConceptScore W4313248601C151730666 @default.
• W4313248601 hasConceptScore W4313248601C167135981 @default.
• W4313248601 hasConceptScore W4313248601C204232928 @default.
• W4313248601 hasConceptScore W4313248601C2779761222 @default.
• W4313248601 hasConceptScore W4313248601C2780849966 @default.
• W4313248601 hasConceptScore W4313248601C2781461381 @default.

• next